Clinical trials: Renal Failure, End Stage
End Stage Renal Disease
Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)
To conduct a pragmatic randomized clinical trial in which the researchers will determine the mortality impact of a protocol whereby all hemodialysis patients receive an oral, protein-based nutritional supplement during the…
- Trial name
- HELPS-HD (NCT02933151)
- Testing
- Nutritional Supplement
- Where
- 2 sites in United States
- Volunteers
- 10,457 people
- Sponsor
- Dialysis Clinic, Inc.
Renal Impairment, Hemodialysis
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
- Trial name
- NCT05099445
- Testing
- INCB000928
- Where
- 5 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Diabetes, Chronic Kidney Disease
Glycaemic Response to Oral Nutrition Support During Haemodialysis
Patients with kidney, or renal, failure require life-saving treatment with regular dialysis. Dialysis is a form of treatment that simulates some kidney functions; to remove harmful waste products and extra water from the blood.
- Conditions
- Diabetes, Chronic Kidney Disease, End Stage Renal Failure on Dialysis
- Trial name
- GRO-HD (NCT02989688)
- Testing
- Nepro HP (Abbott Nutrition), Fortisip compact protein 125 ml + Calogen 20ml (Nutricia), Fortisip compact 125 ml (Nutricia)
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- King's College Hospital NHS Trust
Hypertension
Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure
This project aims at investigating the genetic, genomic and proteomic basis of hypertension and susceptibility to hypertension-related end organ damage (renal damage and heart failure).
- Trial name
- Hypercare (NCT02430805)
- Testing
- dna extraction and genotyping
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
End Stage Renal Disease, Hemolysis
Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access
The investigators propose a randomized study to compare bovine carotid artery (BCA) biologic grafts and expanded polytetrafluoroethylene grafts (ePTFE) for permanent hemodialysis access.
- Conditions
- End Stage Renal Disease, Hemolysis, Arteriovenous Graft
- Trial name
- NCT03300024
- Testing
- Expanded polytetrafluoroethylene Graft, Bovine Carotid Artery Graft
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Renal Insufficiency
A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function
The purpose of this study is to determine the pharmacokinetic (how the drug concentrations change over time) profile of abiraterone acetate 1000 mg when administered as a single dose in male participants with impaired renal…
- Trial name
- NCT01715259
- Testing
- Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cougar Biotechnology, Inc.
End-Stage Renal Disease
L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile.
- Trial name
- NCT00851838
- Testing
- L-Carnitine
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Iperboreal Pharma Srl
Oxidative Stress
Effect of Omega 3 on Oxidative Stress and Nutritional Status of Children on Regular Dialysis
evaluaion the effects of oral omega-3 supplementation on nutritional status and oxidative stress in pediatric patients with end stage renal disease on regular hemodialysis
- Trial name
- NCT06268184
- Testing
- D3 LAB SYRUP
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Tanta University
Hypertension Secondary to Renal Disease
Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy
The study is designed to investigate the efficacy of renal nerve denervation in treating drug-resistant hypertension in patients with end stage renal disease.
- Trial name
- TreatDialRDN (NCT01881035)
- Testing
- Renal nerve denervation
- Where
- Finland
- Volunteers
- 6 people
- Sponsor
- Turku University Hospital
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Diabetic Kidney Disease (DKD)
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group.
- Trial name
- NCT07034807
- Testing
- the traditional Chinese medicine prescription ' Shenzhuo Decoction ', basic treatment
- Where
- 5 sites in China
- Volunteers
- 228 people
- Sponsor
- Liu Hongfang
Chronic Kidney Disease, End Stage Kidney Disease
Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease
Kidney disease patients have a variety of bone disorders that result in bone loss and fractures. The mechanisms of these bone disorders are not clear but may be related to abnormal modification of a bone protein known as…
- Conditions
- Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy
- Trial name
- NCT03626246
- Testing
- Kidney disease
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
End Stage Kidney Disease, Chronic Kidney Diseases
The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in…
- Conditions
- End Stage Kidney Disease, Chronic Kidney Diseases, Kidney Failure, Kidney Insufficiency
- Trial name
- WAVE-Global (NCT04626427)
- Testing
- WavelinQ™ EndoAVF System
- Where
- 3 sites in Belgium, Greece and 1 more
- Volunteers
- 21 people
- Sponsor
- C. R. Bard
Renal Disease, End-Stage, Renal Insufficiency, Chronic
Bosutinib In Subjects With Renal Impairment
This is a two-staged study of a single dose of 200 mg of bosutinib given to subjects with renal impairment and matching healthy volunteers.
- Conditions
- Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
- Trial name
- NCT01233882
- Testing
- Bosutinib
- Where
- 5 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pfizer
End-stage Renal Disease
The Microcirculation, Dialysis Modality and Sequestered Salt
The aim of this clinical trial is to investigate the effect of 5 different dialysis treatments (combinations of dialysis mode and dialysis fluid sodium content) on the microcirculation (MC) and sequestered sodium content (SSC) in…
- Trial name
- MIMOSA (NCT06327750)
- Testing
- Hemodialysis (DNa = PNa), Hemodialysis (DNa<PNa), Hemodialysis after isolated ultrafiltration (DNa=PNa)
- Where
- 2 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Amsterdam UMC, location VUmc
Chronic Renal Failure
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or…
- Trial name
- NCT02331680
- Testing
- OPC-41061
- Where
- 4 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
End Stage Renal Failure on Dialysis, Vascular Calcification
Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum
The study aims to determine the effect size of magnesium and bicarbonate supplementation as a basis for future randomized controlled trials aiming at the T50-guided improvement of hard clinical endpoints in dialysis patients.
- Trial name
- BicMag (NCT02621762)
- Testing
- Magnesium, Bicarbonate
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
End-Stage Renal Disease
Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients
Patient failure to take medications as prescribed (medication non-adherence) is now identified as an important cause of kidney transplant failure.
- Trial name
- OnceDaily (NCT02426502)
- Testing
- Conversion to Advagraf, conversion of non-immunosuppressant drugs to once daily, Conversion to once daily MPA
- Where
- 3 sites in Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
End Stage Renal Disease
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who…
- Trial name
- PRIME (NCT01286012)
- Testing
- Soluble Ferric Pyrophosphate in liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 108 people
- Sponsor
- Rockwell Medical Technologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.